Literature DB >> 3977303

Tetrabenazine induces acute dystonic reactions.

R E Burke, A Reches, M M Traub, J Ilson, M Swash, S Fahn.   

Abstract

Four patients suffered acute dystonic reactions caused by tetrabenazine. Because dystonic reactions have previously been reported only after dopamine receptor blockade and not with dopamine depletion, it is likely that the ability of tetrabenazine to induce acute dystonia is due to its dopamine receptor blocking properties. Because tetrabenazine can induce acute dystonia even when combined with alpha-methyl-p-tyrosine, presynaptic dopamine stores may not be necessary for these reactions to occur.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3977303     DOI: 10.1002/ana.410170217

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  13 in total

1.  Antipsychotic-induced movement disorders: evaluation and treatment.

Authors:  Maju Mathews; Sylvia Gratz; Babatunde Adetunji; Vinu George; Manu Mathews; Biju Basil
Journal:  Psychiatry (Edgmont)       Date:  2005-03

2.  Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study.

Authors:  Itzhak Kimiagar; Evgenia Dobronevsky; Tatiana Prokhorov; Ala Miniovitz; Jose M Rabey
Journal:  J Neurol       Date:  2011-11-09       Impact factor: 4.849

3.  Tetrabenazine in the treatment of senile vocal tics.

Authors:  P Vieregge
Journal:  J Neurol       Date:  1987-12       Impact factor: 4.849

Review 4.  Movement disorder emergencies.

Authors:  Steven J Frucht
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

Review 5.  Cervical dystonia pathophysiology and treatment options.

Authors:  M Velickovic; R Benabou; M F Brin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  Movement disorder emergencies.

Authors:  Kathleen L Poston; Steven J Frucht
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

7.  Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington's Disease-Related Chorea.

Authors:  Tatiana Yero; Jose A Rey
Journal:  P T       Date:  2008-12

Review 8.  Tourette's syndrome and role of tetrabenazine: review and personal experience.

Authors:  Mauro Porta; Marco Sassi; Mario Cavallazzi; Maurizio Fornari; Arianna Brambilla; Domenico Servello
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 9.  Commentary: Dopaminergic dysfunction in DYT1 dystonia.

Authors:  Thomas Wichmann
Journal:  Exp Neurol       Date:  2008-04-26       Impact factor: 5.330

Review 10.  Acute dystonia induced by neuroleptic drugs.

Authors:  N M Rupniak; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.